Abbott Laboratories
Abbott Laboratories Announces Blackout Period for Employee Benefit Plans
Summary
Abbott Laboratories has announced a temporary suspension of trading under its employee benefit plans due to administrative changes, including changes to the recordkeeper, trustee, and custodian. The blackout period, which is expected to begin on December 24, 2025, and end during the week of January 11, 2026, restricts plan participants from engaging in transactions involving the assets held in their plan accounts. A notice regarding the blackout period was sent to directors and executive officers on November 21, 2025.
Profitelligence Alerts
Get alerts for ABT
Be first to know when Abbott Laboratories files with the SEC.
Filing Categories
Advertisement
About Abbott Laboratories
Abbott Laboratories, a globally renowned company, specializes in the development and production of healthcare and medical products. Founded in 1888 and headquartered in Abbott Park, Illinois, Abbott is a pivotal entity in the healthcare sector. The company provides essential products spanning diagnostics, medical devices, nutritional products, and branded generic pharmaceuticals. Notably, Abbott's extensive diagnostic solutions include immunoassays and molecular diagnostics, crucial for medical testing and healthcare management. Its medical devices division produces cardiovascular and neuromodulation products, enhancing patient care across diverse medical practices. Abbott’s nutritional segment, featuring well-known brands like Similac and Ensure, supports health and wellness across various demographics. Serving markets globally, Abbott Laboratories plays a critical role in advancing healthcare infrastructure and delivering innovative solutions that address evolving health challenges worldwide. As a significant player in the life sciences field, Abbott's contributions significantly influence patient outcomes and healthcare delivery systems.
Official SEC Documents
Advertisement